Written by Jane Aubrey
AbelZeta Pharma has received FDA clearance to begin U.S. clinical development of Prizlon-cel, an anti-CD20/CD19 bispecific CAR-T therapy for relapsed or refractory large B-cell lymphoma. The clearance matters because it targets two difficult clinical settings: patients who have already relapsed after a CAR-T therapy and patients earlier in treatment who have not yet received a CAR-T product. Both groups need better options, but they also require evidence that will be more demanding than an encouraging early data set.
The company announced the IND clearance on August 16. Prizlon-cel, also known as C-CAR039, is designed to target both CD20 and CD19, two B-cell antigens. AbelZeta regained worldwide development, regulatory, manufacturing and commercialization rights to the program in July and is now working with the FDA to finalize U.S. protocols for third-or-later-line disease after prior CAR-T treatment and second-line disease in CAR-T-naïve patients.
The dual-target design is the central scientific proposition. CAR-T therapy works by engineering a patient’s own T cells to recognize a cancer-associated antigen. Single-target CD19 CAR-T products have transformed treatment for several B-cell malignancies, but relapse can occur when tumors reduce or lose the targeted antigen, when engineered cells do not persist, or when the tumor microenvironment suppresses immune activity. Targeting CD20 and CD19 together is intended to reduce one route by which malignant B cells may escape immune recognition.
AbelZeta’s early Chinese data are promising but should be interpreted carefully. In 48 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company reported an overall response rate of 91.5% and a complete-response rate of 85.1%. Median progression-free survival was reported at 60.1 months after a median follow-up of 53.9 months. Those are striking numbers in a heavily treated disease setting, particularly because durable responses are the feature that separates a meaningful cell therapy from a transient response.
Yet small, early clinical cohorts are not a substitute for a controlled global development program. Patient selection, manufacturing consistency, prior treatment history, follow-up procedures and disease characteristics can all affect outcomes. The central U.S. question is not whether Prizlon-cel can produce responses; it is whether it can reproduce durable benefit and an acceptable safety profile in the specific populations the company plans to study.
The post-CAR-T population is especially challenging. Patients who relapse after an approved CAR-T therapy often have aggressive disease and limited remaining options. A second cellular therapy must show that its biological design has overcome a meaningful mechanism of resistance rather than simply duplicate the first treatment’s pathway. The CAR-T-naïve second-line setting creates a different test: the therapy must compete against established treatment strategies where efficacy, safety, manufacturing turnaround time and hospital capacity all influence physician choice.
Manufacturing will be a strategic variable. Autologous CAR-T therapies are made from an individual patient’s cells, creating a chain of collection, production, testing and delivery that can be difficult for ill patients to navigate. AbelZeta says it operates its own GMP facilities, an advantage if it enables control over production and scale. But U.S. development must demonstrate that a manufacturing process used in prior studies can be transferred, validated and reliably executed for a new regulatory environment.
The company’s registrational Phase II study in China for CAR-T-naïve relapsed or refractory large B-cell lymphoma remains ongoing. That continuing program could add useful evidence, but regulatory decisions will depend on the design and results of the relevant studies, not on the IND clearance alone.
Prizlon-cel’s entry into the U.S. clinic is a meaningful step because it brings a dual-target CAR-T approach to patients with high unmet need. The real milestone will come later: evidence that a biologically plausible solution to antigen escape can deliver durable benefit after the rigor of larger, well-controlled trials.
